Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial
BackgroundAtherosclerosis can develop as a result of an increase in oxidative stress and concurrently rising levels of inflammation. Astaxanthin (AX), a red fat-soluble pigment classified as a xanthophyll, may be able to prevent the vascular damage induced by free radicals and the activation of infl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2023.1104169/full |
| _version_ | 1827979233100562432 |
|---|---|
| author | Marzieh Heidari Maryam Chaboksafar Mohammad Alizadeh Bahram Sohrabi Sorayya Kheirouri |
| author_facet | Marzieh Heidari Maryam Chaboksafar Mohammad Alizadeh Bahram Sohrabi Sorayya Kheirouri |
| author_sort | Marzieh Heidari |
| collection | DOAJ |
| description | BackgroundAtherosclerosis can develop as a result of an increase in oxidative stress and concurrently rising levels of inflammation. Astaxanthin (AX), a red fat-soluble pigment classified as a xanthophyll, may be able to prevent the vascular damage induced by free radicals and the activation of inflammatory signaling pathways. The objective of the current study is to assess the effects of AX supplementation on cardiometabolic risk factors in individuals with coronary artery disease (CAD).MethodsThis randomized double-blind placebo-controlled clinical trial was conducted among 50 CAD patients. Participants were randomly allocated into two groups to intake either AX supplements (12 mg/day) or placebo for 8 weeks. Lipid profile, glycemic parameters, anthropometric indices, body composition, Siruin1 and TNF-α levels were measured at baseline and after 8 weeks.ResultsBody composition, glycemic indices, serum levels of TNF-α, Sirtuin1 did not differ substantially between the AX and placebo groups (p > 0.05). The data of AX group showed significant reduction in total cholesterol (−14.95 ± 33.57 mg/dl, p < 0.05) and LDL-C (−14.64 ± 28.27 mg/dl, p < 0.05). However, TG and HDL-C levels could not be affected through AX supplementation.ConclusionOur results suggest that AX supplementation play a beneficial role in reducing some components of lipid profile levels. However, further clinical investigations in CAD patients are required to obtain more conclusive findings.Clinical trial registrationwww.Irct.ir., identifier IRCT20201227049857N1. |
| first_indexed | 2024-04-09T21:34:03Z |
| format | Article |
| id | doaj.art-bd390e0034114e0ca073ed703fb18ca5 |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-04-09T21:34:03Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-bd390e0034114e0ca073ed703fb18ca52023-03-27T05:48:35ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2023-03-011010.3389/fnut.2023.11041691104169Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trialMarzieh Heidari0Maryam Chaboksafar1Mohammad Alizadeh2Bahram Sohrabi3Sorayya Kheirouri4Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, IranCardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Nutrition, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, IranBackgroundAtherosclerosis can develop as a result of an increase in oxidative stress and concurrently rising levels of inflammation. Astaxanthin (AX), a red fat-soluble pigment classified as a xanthophyll, may be able to prevent the vascular damage induced by free radicals and the activation of inflammatory signaling pathways. The objective of the current study is to assess the effects of AX supplementation on cardiometabolic risk factors in individuals with coronary artery disease (CAD).MethodsThis randomized double-blind placebo-controlled clinical trial was conducted among 50 CAD patients. Participants were randomly allocated into two groups to intake either AX supplements (12 mg/day) or placebo for 8 weeks. Lipid profile, glycemic parameters, anthropometric indices, body composition, Siruin1 and TNF-α levels were measured at baseline and after 8 weeks.ResultsBody composition, glycemic indices, serum levels of TNF-α, Sirtuin1 did not differ substantially between the AX and placebo groups (p > 0.05). The data of AX group showed significant reduction in total cholesterol (−14.95 ± 33.57 mg/dl, p < 0.05) and LDL-C (−14.64 ± 28.27 mg/dl, p < 0.05). However, TG and HDL-C levels could not be affected through AX supplementation.ConclusionOur results suggest that AX supplementation play a beneficial role in reducing some components of lipid profile levels. However, further clinical investigations in CAD patients are required to obtain more conclusive findings.Clinical trial registrationwww.Irct.ir., identifier IRCT20201227049857N1.https://www.frontiersin.org/articles/10.3389/fnut.2023.1104169/fullcoronary artery diseaseastaxanthinlipid profileglycemic indicesinflammation |
| spellingShingle | Marzieh Heidari Maryam Chaboksafar Mohammad Alizadeh Bahram Sohrabi Sorayya Kheirouri Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial Frontiers in Nutrition coronary artery disease astaxanthin lipid profile glycemic indices inflammation |
| title | Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial |
| title_full | Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial |
| title_fullStr | Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial |
| title_full_unstemmed | Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial |
| title_short | Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-α levels in patients with coronary artery disease: A randomized, double-blind, placebo-controlled clinical trial |
| title_sort | effects of astaxanthin supplementation on selected metabolic parameters anthropometric indices sirtuin1 and tnf α levels in patients with coronary artery disease a randomized double blind placebo controlled clinical trial |
| topic | coronary artery disease astaxanthin lipid profile glycemic indices inflammation |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2023.1104169/full |
| work_keys_str_mv | AT marziehheidari effectsofastaxanthinsupplementationonselectedmetabolicparametersanthropometricindicessirtuin1andtnfalevelsinpatientswithcoronaryarterydiseasearandomizeddoubleblindplacebocontrolledclinicaltrial AT maryamchaboksafar effectsofastaxanthinsupplementationonselectedmetabolicparametersanthropometricindicessirtuin1andtnfalevelsinpatientswithcoronaryarterydiseasearandomizeddoubleblindplacebocontrolledclinicaltrial AT mohammadalizadeh effectsofastaxanthinsupplementationonselectedmetabolicparametersanthropometricindicessirtuin1andtnfalevelsinpatientswithcoronaryarterydiseasearandomizeddoubleblindplacebocontrolledclinicaltrial AT bahramsohrabi effectsofastaxanthinsupplementationonselectedmetabolicparametersanthropometricindicessirtuin1andtnfalevelsinpatientswithcoronaryarterydiseasearandomizeddoubleblindplacebocontrolledclinicaltrial AT sorayyakheirouri effectsofastaxanthinsupplementationonselectedmetabolicparametersanthropometricindicessirtuin1andtnfalevelsinpatientswithcoronaryarterydiseasearandomizeddoubleblindplacebocontrolledclinicaltrial |